“…The trials included in this analysis encompassed a range of patient characteristics (e.g., UA, NSTEMI, and STEMI), therapeutic regimens (e.g., elective PCI, primary PCI), and adjunctive drugs. In another meta-analysis, which involved 19 trials of 20 137 patients, 30-day and 6-month mortality were both significantly reduced for those receiving IIb/IIIa receptor antagonists (Tables 24a and 24b) (64,111,112,191,195,198,200,201,442,443,(701)(702)(703)(704)(705)(706)(707)(708)(709)(710)(711)(712)(713)(714)(715)(716)(717). Thus, patients undergoing PCI can expect a lower 30-day mortality when GP IIb/IIIa therapy is utilized.…”